Cargando…

Modulation of immune cell infiltrate with sunitinib to improve anti-PD1 therapy in preclinical tumor model

Detalles Bibliográficos
Autores principales:	Rayman, Patricia, Diaz-Montero, C Marcela, Yang, Yu, Rini, Brian, Elson, Paul, Finke, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649303/ http://dx.doi.org/10.1186/2051-1426-3-S2-P310

Ejemplares similares

IL-12 stimuli during ex vivo expansion not only prevents the upregulation of PD1 on tumor infiltrating adoptively transferred T cells but also on endogenous TILs which results in effective tumor regression
por: Diaz-Montero, C Marcela, et al.
Publicado: (2014)

Accumulation of MDSC subsets in renal cell carcinoma correlates with grade and progression free survival, and is associated with intratumoral expression of IL-1β, IL-8 and CXCL5
por: Najjar, Yana G, et al.
Publicado: (2014)

Ex vivo conditioning with IL-12 decreases T cell sensitivity to intratumoral INF-γ-induced apoptosis following adoptive transfer
por: Diaz-Montero, C Marcela, et al.
Publicado: (2015)

Preclinical to clinical translation of anti-PD-1 blockade
por: Hirsch, Heather, et al.
Publicado: (2015)

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
por: Spahn, Jessica, et al.
Publicado: (2015)

Differential gene expression in G-MDSC and neutrophils from renal cell carcinoma patients
por: Ko, Jennifer, et al.
Publicado: (2014)

Proangiogenic neutrophilic-myeloid-derived suppressor cells emerge via two parallel pathways in renal cell carcinoma and melanoma
por: Ko, Jennifer, et al.
Publicado: (2013)

Neutrophils from renal cell carcinoma patients show increased expression of immunosuppressive and angiogenic gene profile
por: Obery, Dana R, et al.
Publicado: (2013)

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer
por: Sakellariou-Thompson, Donastas, et al.
Publicado: (2015)

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model
por: Diaz-Montero, C Marcela, et al.
Publicado: (2016)

Enhancement of T cell immunity to osteosarcoma through modulation of PD-1/PD-L1 interactions
por: Lussier, Danielle M, et al.
Publicado: (2013)

Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma
por: Zahoor, Haris, et al.
Publicado: (2018)

Sunitinib effectively reduces clonogenic acute myeloid leukemia cells in vitro
por: Ahmed, Farid, et al.
Publicado: (2014)

Transduction of human dendritic cells with adenovirus encoding anti-PD-1 reduces PD-1 expression on co-cultured T cells
por: Patricia, Santos, et al.
Publicado: (2014)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
por: Johnson, Christopher B, et al.
Publicado: (2014)

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
por: Sun, Lillian, et al.
Publicado: (2018)

Anti-HIV and immune modulating activities of IND02
por: Biedma, ME, et al.
Publicado: (2012)

PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer
por: Concha-Benavente, Fernando, et al.
Publicado: (2015)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastasis
por: Dhupkar, Pooja M, et al.
Publicado: (2015)

Anti-tumor characteristics of radiation-induced tumor-infiltrating neutrophils
por: Takeshima, Tsuguhide, et al.
Publicado: (2014)

Autologous tumor lysate-loaded dendritic cell vaccination combined with Sunitinib for metastatic renal cell carcinoma
por: Kakimi, Kazuhiro, et al.
Publicado: (2014)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

Image guided cryoablation of cancer with intra-tumoral injection of anti-CTLA-4 and PD-1 immune check-point inhibitors
por: Rosenberg, Mark A, et al.
Publicado: (2015)

Preclinical pharmacodynamics and safety profiling of AZD9773: a novel anti-TNFα polyclonal immune ovine Fab similar to D-CytoFab
por: Newham, P, et al.
Publicado: (2011)

Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model
por: Lyon, Amanda, et al.
Publicado: (2014)

Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade
por: Mueller, Antonia MS, et al.
Publicado: (2014)

Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
por: Vandeveer, Amanda, et al.
Publicado: (2015)

MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
por: Irving, Bryan A, et al.
Publicado: (2013)

Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients
por: Dronca, Roxana, et al.
Publicado: (2015)

Co-expression networks identify distinct immune infiltrates in hepatocellular carcinoma
por: Chiang, Derek Y, et al.
Publicado: (2015)

Immune infiltrates impact on the prediction of prognosis and response to immunotherapy of melanoma patients
por: Vasaturo, Angela, et al.
Publicado: (2015)

P13. Intra-tumoral and surrogate immune responses in patients treated with the engineered anti-PD-L1 antibody (MPDL3280A)
por: Kowanetz, M, et al.
Publicado: (2014)

Therapeutic efficacy of Sunitinib and other broad spectrum receptor tyrosine kinase inhibitors (RTKI) in bleomycin-induced pulmonary fibrosis
por: Knoerzer, D, et al.
Publicado: (2013)

Infiltration of immune cells into cancer cell/stroma cell 3D microtissues
por: Koeck, Stefan, et al.
Publicado: (2015)

Immune mediated therapy and MEK inhibition: preclinical assessment of immunobiology and combination activity in vitro and in vivo
por: Stewart, Ross, et al.
Publicado: (2014)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
por: Powles, Thomas, et al.
Publicado: (2015)

Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model
por: Sola, Caroline, et al.
Publicado: (2013)

Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771
por: Gray, Michael, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kgiv5pb9tdvsj9v28jff43320s